Apimeds Pharmaceuticals US Inc (APUS) Stock Analysis
Verdict: AVOID
Severe cash burn ($6.2M/qtr) and crypto pivot create existential dilution risk — litigation and pre-revenue profile override recent spikes.
Investment score: 16/100
Analysis as of
Is Apimeds Pharmaceuticals US Inc stock worth reviewing? The TradeMates thesis
Apimeds US presents an extreme-risk micro-cap profile marked by zero revenue, an ongoing cash burn ($6.18M in Q2 2026) that leaves under one month of cash runway ($0.28M cash), and class-action litigation following a controversial pivot into crypto infrastructure.
7-factor investment score
- Valuation: 20/100 (weight 20%)
- Financial Health: 5/100 (weight 15%)
- Technical Momentum: 35/100 (weight 15%)
- Earnings Quality: 5/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 10/100 (weight 10%)
- Risk-Adjusted Return: 15/100 (weight 15%)
Apimeds Pharmaceuticals US Inc opportunities and risks
What speaks for APUS
- Execution on MindChain Layer 2 blockchain deployment scheduled for October 2026
What speaks against APUS
- Imminent insolvency and extreme shareholder dilution due to near-zero cash balance ($0.28M)
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| APUS | n/a | 0.0x | n/a | 0.0% | 0.0% | -129.3% |
| INTS | n/a | 0.0x | n/a | 0.0% | 0.0% | -93.3% |
| PHIO | n/a | 0.0x | 0.1x | 0.0% | 0.0% | -105.7% |
| BCLI | n/a | 0.0x | n/a | 0.0% | 0.0% | -35.7% |
| OTLC | 0.0x | 35.5x | n/a | 100.0% | 98998.0% | -17.2% |
| LSTA | n/a | 110.2x | n/a | 95.0% | -14621.0% | -111.8% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -93.3% |
Frequently asked questions about Apimeds Pharmaceuticals US Inc (APUS)
Is APUS stock a good investment?
The TradeMates model rates Apimeds Pharmaceuticals US Inc as AVOID with an investment score of 16/100. Apimeds US presents an extreme-risk micro-cap profile marked by zero revenue, an ongoing cash burn ($6.18M in Q2 2026) that leaves under one month of cash runway ($0.28M cash), and class-action litigation following a controversial pivot into crypto infrastructure. This is algorithmic model output, not personal investment advice.
Is APUS stock a buy?
The TradeMates model verdict for APUS is AVOID with an investment score of 16/100. Treat this as a model signal to review, not a personal buy recommendation.